Give your patients the BASAGLAR Experience™
The BASAGLAR Experience offers resources designed to help patients accept, start, and stay on insulin.
Patients may be hesitant to begin basal insulin. The BASAGLAR Experience support resources may help address their initial concerns during the Insulin negotiation phase as well as help reinforce important information at home when Doing it on their own.
In patients with type 1 diabetes, BASAGLAR must be used concomitantly with short-acting insulin.1
Scroll through the steps to learn more about the BASAGLAR Experience and the resources designed to help patients accept, start, and stay on insulin.
SELECT SAFETY INFORMATION
CONTRAINDICATIONS
BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or one of its excipients.
WARNINGS AND PRECAUTIONS
BASAGLAR KwikPen® must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.
Help address concerns and clear misconceptions
Living with long-acting insulin video
Video that helps dispel patient myths about insulin; available on the Beginning BASAGLAR App, online and as an in-office resource
Insulin discussion tool
Designed to help HCPs guide patients through the importance of different diabetes treatment options
Ask your BASAGLAR representative
SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.
Hypoglycemia is the most common adverse reaction associated with insulins, including BASAGLAR. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.
Help patients learn how to inject
Instructional video
Step-by-step demonstration on how to inject; available on the Beginning BASAGLAR App, online and as an in-office resource
Injection demo kit and Instructions for Use
Helps you demonstrate KwikPen® injection in your office
Ask your BASAGLAR representative
SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Accidental mix-ups between another insulin glargine product (100 units/mL) and other insulins, particularly rapid-acting insulins, have been reported. To avoid medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.
Help patients learn about BASAGLAR
Patient brochure
Important information to help your patients begin BASAGLAR
Ask your BASAGLAR representative
Sample kit with needles
Sample with pen needles and information about savings on prescriptions
Ask your BASAGLAR representative
Help make treatment more affordable
BASAGLAR formulary coverage
Ask your BASAGLAR representative for a local access sheet with specific coverage information for your area
SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.
Help reinforce important information at home
Beginning BASAGLAR app
An interactive experience that helps patients relax and guides them through injection using their KwikPen®
Our mobile app gives you information you need to learn to inject—the Injection Instruction Video, Interactive Injection Guide, and more.
DOWNLOAD FOR iPHONE®/iPAD®:
- Open the App Store, tap “Search”
- Type “Beginning BASAGLAR,” select it, and tap “GET”
DOWNLOAD FOR ANDROID™ DEVICES:
- Open the Google Play Store and type “Beginning BASAGLAR” in the search bar
- Select it and tap “INSTALL”
BASAGLAR patient website
An online resource with easily accessible BASAGLAR information and insulin education
SELECT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
All insulin products, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.